A recent Cochrane analysis of the findings in these studies concluded that ‘. [SMART] can reduce the risk of asthma exacerbations needing oral corticosteroids in comparison with fixed dose maintenance inhaled corticosteroids . [SMART] has not been demonstrated to significantly reduce exacerbations in comparison with current best practice’.